Pivoting from clinical to commercial, MorphoSys loses CSO by Ben Adams Thursday, November 21, 2019 After the loss of its longtime CEO at the start of the year, a morphing MorphoSys is now losing its CSO.
New discoveries in ovarian cancer and neurology—News of Note by Arlene Weintraub Monday, April 1, 2019 The week’s biotech discoveries included an I-O triple therapy against ovarian cancer and a single protein target for three diseases.
Merck KGaA, F-Star in bispecific biobucks bonanza deal by Ben Adams Monday, June 5, 2017 It's a marriage of science for Germany’s Merck and Cambridge, U.K.-based F-Star as the two pair for a new bispecific research deal.